1
|
Yang J, Nugroho AS, Yamauchi K, Yoshioka K, Zheng J, Wang K, Kato K, Kuroyanagi S, Iwata A. Efficacy of interferon treatment for chronic hepatitis C predicted by feature subset selection and support vector machine. J Med Syst 2007; 31:117-23. [PMID: 17489504 DOI: 10.1007/s10916-006-9046-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Chronic hepatitis C is a disease that is difficult to treat. At present, interferon might be the only drug, which can cure this kind of disease, but its efficacy is limited and patients face the risk of side effects and high expense, so doctors considering interferon must make a serious choice. The purpose of this study is to establish a simple model and use the clinical data to predict the interferon efficacy. This model is a combination of Feature Subset Selection and the Classifier using a Support Vector Machine (SVM). The study indicates that when five features have been selected, the identification by the SVM is as follows: the identification rate for the effective group is 85%, and the ineffective group 83%. Analysis of selected features show that HCV-RNA level, hepatobiopsy, HCV genotype, ALP and CHE are the most significant features. The results thus serve for the doctors' reference when they make decisions regarding interferon treatment.
Collapse
Affiliation(s)
- Jun Yang
- Department of Medical Information and Management Science, Graduate School of Medicine, Nagoya University, 65, Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Tanaka T, Yabusako T, Yamashita T, Kondo K, Nishiguchi S, Kuroki T, Monna T. Contribution of Hepatitis C Virus to the Progression of Alcoholic Liver Disease. Alcohol Clin Exp Res 2006. [DOI: 10.1111/j.1530-0277.2000.tb00024.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Takashi Tanaka
- Department of Public Health; Osaka City University College of Nursing; Osaka Japan
| | - Tsuneo Yabusako
- Department of Public Health; Osaka City University College of Nursing; Osaka Japan
| | - Terumi Yamashita
- Department of Public Health; Osaka City University College of Nursing; Osaka Japan
| | - Kyoko Kondo
- Department of Public Health; Osaka City University College of Nursing; Osaka Japan
| | - Shuhei Nishiguchi
- Third Department of Internal Medicine; Osaka City University Medical School; Osaka Japan
| | - Tetsuo Kuroki
- Third Department of Internal Medicine; Osaka City University Medical School; Osaka Japan
| | | |
Collapse
|
3
|
Eguchi Y, Mizuta T, Yasutake T, Hisatomi A, Iwakiri R, Ozaki I, Fujimoto K. High serum leptin is an independent risk factor for non-response patients with low viremia to antiviral treatment in chronic hepatitis C. World J Gastroenterol 2006; 12:556-60. [PMID: 16489668 PMCID: PMC4066087 DOI: 10.3748/wjg.v12.i4.556] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To determine whether body weight and/or serum leptin were independent predictors of response to antiviral treatment in patients with chronic hepatitis C.
METHODS: A retrospective evaluation was performed in 139 patients with chronic hepatitis C treated with interferon (IFN) from 1996 to 2000. Sustained response was defined as negative by hepatitis C virus (HCV) RNA analysis using PCR and normal transaminase at 24 wk after cessation of IFN therapy. Patients who remained positive for HCV RNA at the end of IFN treatment were defined as resistant to IFN therapy. Sex, age, body mass index (BMI) (≥ 25 vs < 25), complication of diabetes mellitus, serum leptin level (≥ 8.0 μg/L vs < 8.0 μg/L), and the stage of liver fibrosis by needle biopsy (F1/F2 vs F3/F4) were examined.
RESULTS: Sustained response was achieved in 33 patients (23.7%), while others failed to show a response to IFN therapy. Overall, the factors associated with sustained antiviral effects were HCV-RNA load, HCV genotype, serum leptin level, and stage of liver fibrosis evaluated by univariate analysis. BMI was not associated with any therapeutic effect of IFN. Multivariate analysis indicated that HCV-RNA load was a significant risk factor, but among the patients with low viremia (HCV-RNA < 100 MU/L), leptin level was an independent risk factor for IFN resistance. Namely, a high level of serum leptin attenuated the effect of IFN on both male and female patients with low viremia.
CONCLUSION: High serum leptin level is a negative predictor of response to antiviral treatment in chronic hepatitis C with low viremia.
Collapse
Affiliation(s)
- Yuichiro Eguchi
- Department of Internal Medicine, Saga Medical School, Saga, 5-1-1 Nabeshima, Saga 849-8501, Japan
| | | | | | | | | | | | | |
Collapse
|
4
|
He Y, Katze MG. To interfere and to anti-interfere: the interplay between hepatitis C virus and interferon. Viral Immunol 2002; 15:95-119. [PMID: 11952150 DOI: 10.1089/088282402317340260] [Citation(s) in RCA: 70] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
As popular strategies used by numerous viruses, interception of interferon (IFN) signaling and inhibition of IFN-induced antiviral functions allow viruses to evade the host immune response and set up successful infections. Hepatitis C virus (HCV), the leading cause of chronic liver disease worldwide and a major public health hazard, causes persistent infection in the majority of infected individuals. IFN-based therapies, currently the only ones available for HCV infection, have been unable to eliminate viral infection in the majority of patients, and many studies suggest that HCV possesses mechanisms to antagonize the IFN-induced antiviral response. Multiple viral, host, and IFN-associated factors have been implicated in the interplay between HCV and IFN. Two viral proteins, NS5A and E2, became the focus of much attention and extensive study because of their abilities to inhibit IFN-induced, double-stranded RNA-activated protein kinase (PKR), a major mediator of the IFN-induced biologic response, and to perturb the IFN signaling pathway. In this review, we discuss the significance of the interferon sensitivity determining region (ISDR) within NS5A, which has been the subject of intense debates. In addition, we discuss the potential mechanisms by which NS5A interferes with IFN signaling and the current working models. Further understanding of the molecular mechanisms underlying the interaction between HCV and IFN will likely facilitate improvement of current IFN-based therapies and development of novel treatments for the HCV pandemic. Future HCV research will benefit from both the development of efficient, convenient model systems for viral propagation, and the utilization of high throughput, genomic-scale approaches.
Collapse
Affiliation(s)
- Yupeng He
- Department of Microbiology, School of Medicine, University of Washington, 98195, USA
| | | |
Collapse
|
5
|
Abstract
Viral load measurements provide an indication of viral replication, and thereby serve as a valuable tool to guide the initiation of therapy and subsequent changes. Plasma human immunodeficiency viral load strongly predicts the rate of decrease in CD4+ lymphocyte count, and progression to AIDS and death. Furthermore, the efficacy of antiretroviral therapy can be assessed by monitoring changes in plasma human immunodeficiency viral load. Similarly, viral load provides valuable information about the natural history of the hepatitis C virus infection. Hepatitis C viral load can be used to predict the likelihood of response to standard interferon-alpha treatment and other interferon-alpha regimens and to monitor treatment efficacy. Increased understanding of the natural history of the hepatitis C virus infection and the nature of resistance to interferon-alpha therapy suggests that effective treatment regimens must maintain serum levels of interferon-alpha. Ideally, interferon-alpha serum levels should provide constant pressure on the virus and should prevent viral rebound, thereby avoiding continued viral replication and minimizing the potential for emergence of resistant quasi-species. Current regimens designed to address these points include early aggressive intervention, combination drug regimens, prolonged maintenance, and novel interferons. By enabling the design and rapid assessment of new treatment regimens, viral load measurement will revolutionize the clinical management of the hepatitis C virus infection, as it has the HIV.
Collapse
Affiliation(s)
- V G Bain
- Department of Medicine, University of Alberta, Edmonton, Canada
| |
Collapse
|
6
|
Abstract
Interferon plays a critical role in the host's natural defense against viral infections and in their treatment. It is the only therapy for hepatitis C virus (HCV) infection; however, many virus isolates are resistant. Several HCV proteins have been shown to possess properties that enable the virus to evade the interferon-mediated cellular antiviral responses.
Collapse
Affiliation(s)
- D R Taylor
- Department of Molecular Microbiology and Immunology, University of Southern California, School of Medicine, 2011 Zonal Avenue, Los Angeles, CA 90089, USA
| | | | | |
Collapse
|
7
|
Abstract
Interferon-alpha (IFN-alpha), either alone or in combination with ribavirin, is the standard treatment for patients with hepatitis C. However, most patients do not achieve a sustained remission with this treatment regimen. A number of studies have demonstrated that genotype, baseline viral load and/or a decrease in viral load early after treatment induction are the major predictive factors for response to treatment with IFN. Patients with hepatitis C virus (HCV) genotype 1 are more resistant to treatment with IFN, whereas low viral load at baseline and a marked decline in the HCV RNA level during the first 2-12 weeks of IFN therapy are associated with enhanced treatment efficacy. These variables could potentially be used to develop treatment algorithms that tailor therapies for specific clinical situations. Continued development and refinement of such algorithms would facilitate both the selection of patients who are most likely to benefit from therapy and the development of optimal treatment regimens for different patient groups. Predictive factors will also enable clinicians to identify subsets of patients who are not expected to respond well to current treatment. The development of new delivery methods for IFN that produce sustained antiviral pressure may provide a means of treating these previously difficult-to-treat patient groups.
Collapse
Affiliation(s)
- C Trepo
- Hepatitis Research Unit and Liver Unit, Hoteldieu Hospital, Lyon, France
| |
Collapse
|
8
|
Kondili LA, Taliani G, Tosti ME, De Bac C, Pasquazzi C, Mele A. Methodological issues in papers on IFN therapy: time for reappraisal. J Viral Hepat 2000; 7:184-95. [PMID: 10849260 DOI: 10.1046/j.1365-2893.2000.00214.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/09/2022]
Abstract
We conducted an analytical review of 194 full papers on interferon (IFN) therapy for chronic hepatitis C to evaluate current methodology (i.e. study design, criteria for evaluating the efficacy of therapy and predictors of response). Of the papers evaluated, 64 were randomized controlled trials (RCT), 40 were non-randomized controlled trials (NRCT) and 90 were observational studies (OS). The methodological analysis was focused mainly on clinical trials. The number of patients enrolled in RCT was higher compared with the number enrolled in NRCT. Uniform enrolment criteria were used in less than 50% of the trials. Only 20% of RCT and 2.5% of NRCT used criteria for defining sample size. The response rate was calculated on an intention-to-treat basis in 36 of the RCT and in 14 of the NRCT. The outcome of treatment and the criteria employed to define the response to treatment were found to be far from standardized. In 51.5% of the RCT and 42.5% of the NRCT, normalization of alanine aminotransferase (ALT) level at the end of follow-up was the only marker of response studied. Only 57.6% of the trials considered histological evidence as an important outcome. Among the clinical trials, 71.1% evaluated predictors of good response to IFN therapy. In 51% of the OS, ALT normalization by the end of follow-up was the only criterion for defining response. In conclusion, to ensure a high level of reliability in comparing or combining the results of different studies, some basic general requirements must be followed when planning trials on antiviral therapy.
Collapse
Affiliation(s)
- L A Kondili
- Laboratorio di Epidemiologia e Biostatistica, Istituto Superiore di Sanit¿a, Roma, Italy
| | | | | | | | | | | |
Collapse
|
9
|
Vandelli C, Renzo F, Braun HB, Tisminetzky S, Albrecht M, De Palma M, Ranzi A, Di Marco G, Stroffolini T, Baralle F, Ventura E, Michel G. Prediction of successful outcome in a randomised controlled trial of the long-term efficacy of interferon alpha treatment for chronic hepatitis C. J Med Virol 1999; 58:26-34. [PMID: 10223542 DOI: 10.1002/(sici)1096-9071(199905)58:1<26::aid-jmv4>3.0.co;2-w] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
To evaluate the efficacy of a 12-month course of recombinant interferon alpha (IFN-alpha2b), and to assess predictive factors of successful response to IFN therapy in chronic active hepatitis C (HCV CAH), 242 patients with histologically proven HCV CAH were assigned randomly to two groups, one treated with IFN-alpha2b (3 MU three times weekly, intramuscularly), the other untreated. To determine the efficacy of IFN-alpha2b 12 months after therapy, a second liver biopsy was carried out on 100 treated patients and 27 untreated patients. The biochemical, virological, and serological response of patients followed up for at least 50 months after treatment was also evaluated to confirm the efficacy of IFN-alpha2b. The genotypes of infecting HCV, anti-HCV core IgM, and HCV-RNA concentrations were also analysed and the predictors of response determined by univariate and multivariate analyses. Response was defined in terms of the normalisation of aminotransferase activities and the disappearance of HCV-RNA. The overall long-term response was 39.4%. Anti-HCV core IgM levels were significantly lower in long-term responders. Patients with increased levels of IgM anti HCV core (>3.8 sample/cut-off), infected with genotype 1b were nonresponders. Liver histology improved significantly in patients with long-term response. Multivariate analysis identified three independent predictors of the likelihood of long-term response to IFN therapy: age younger than 40 years, basal anti-HCV core IgM levels < or = 3.8, and genotypes other than 1b. These data indicate that the treatment with IFN-alpha2b used in this randomised controlled trial is effective in HCV CAH. Anti-HCV core IgM was the strongest predictor of long-term response in the present study.
Collapse
Affiliation(s)
- C Vandelli
- Dipartimento di Medicina Interna, Università di Modena, Italia.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Mizukoshi E, Kaneko S, Yanagi M, Ohno H, Kaji K, Terasaki S, Shimoda A, Matsushita E, Kobayashi K. Expression of interferon alpha/beta receptor in the liver of chronic hepatitis C patients. J Med Virol 1998; 56:217-23. [PMID: 9783688 DOI: 10.1002/(sici)1096-9071(199811)56:3<217::aid-jmv7>3.0.co;2-a] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Interferon (IFN) demonstrates antiviral activity by binding to receptors on the cell surface. Expression of the IFN receptor in hepatocytes may be directly associated with a hepatitis C virus (HCV) infection and the response to IFN therapy. A competitive PCR method was developed to measure IFN alpha/beta (alphabeta) receptor mRNA in liver samples obtained by needle biopsy. Thirty-one patients with chronic hepatitis C (21 without cirrhosis, 10 with cirrhosis) and six normal subjects were used. Eighteen of the 21 patients without cirrhosis received the IFN therapy. Competitive PCR was carried out using IFN alphabeta receptor gene-specific primers and a specific competitor. Expression of the receptor was detected in all liver samples. There was no association between the expression level and serum alanine aminotransferase level, serum (2'-5') oligo (A) synthetase level, amount of serum HCV RNA, or HCV genotype. The expression level in patients with chronic hepatitis was significantly higher than that in normal livers (P < 0.05) and in cirrhotic livers (P< 0.01). Seven of the 18 patients treated with IFN demonstrated a sustained response to IFN (sustained responders), and the remaining 11 did not (nonsustained responders). The expression level of IFN alphabeta receptor mRNA in the sustained responders was significantly higher than that in the nonsustained responders (P< 0.01). Thus, the expression of IFN alphabeta receptor mRNA may be one of the host factors influencing the response to IFN therapy.
Collapse
MESH Headings
- Adult
- Aged
- Alanine Transaminase/blood
- Blotting, Northern
- Female
- Gene Expression
- Hepacivirus/classification
- Hepacivirus/isolation & purification
- Hepatitis C, Chronic/immunology
- Hepatitis C, Chronic/pathology
- Hepatitis C, Chronic/therapy
- Hepatitis C, Chronic/virology
- Humans
- Interferon-alpha/therapeutic use
- Interferon-beta/therapeutic use
- Liver/chemistry
- Liver/immunology
- Liver/pathology
- Male
- Membrane Proteins
- Middle Aged
- Polymerase Chain Reaction
- RNA, Messenger/analysis
- RNA, Messenger/genetics
- RNA, Viral/blood
- Receptor, Interferon alpha-beta
- Receptors, Interferon/analysis
- Receptors, Interferon/genetics
Collapse
Affiliation(s)
- E Mizukoshi
- First Department of Internal Medicine, Kanazawa University School of Medicine, Ishikawa, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|